Literature DB >> 6861635

Phenytoin-induced lymphadenopathy.

T L Schwinghammer, D L Howrie.   

Abstract

Various lymph node abnormalities have been associated with phenytoin therapy. Four distinct categories of lymphadenopathy have been described: lymphoid hyperplasia, pseudolymphoma, pseudo-pseudolymphoma, and lymphoma. These presentations vary from a benign symptom complex, with enlarged lymph nodes, that is reversible upon drug discontinuance to a true malignant lymphoma that is progressive and ultimately fatal. Benign lymph node hyperplasia and pseudolymphoma may result in erroneous diagnosis and treatment of malignant lymphoma if phenytoin-associated lymphadenopathy has not been considered. We describe a patient who developed enlarged inguinal lymph nodes while receiving chronic phenytoin therapy. An initial diagnosis of malignant lymphoma was made, and recurrent hospitalizations and treatment with cytotoxic drugs ensued. Repeat biopsy, as well as reexamination of the removed nodes, later revealed phenytoin-associated hyperplasia. Patients who develop enlarged lymph nodes while receiving phenytoin should be evaluated carefully so that phenytoin-induced lymphadenopathy may be differentiated from true malignant lymphoma and appropriate treatment may be given.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6861635     DOI: 10.1177/106002808301700608

Source DB:  PubMed          Journal:  Drug Intell Clin Pharm        ISSN: 0012-6578


  3 in total

1.  Acute lymphadenopathy complicating quinidine therapy.

Authors:  C P Lau; K L Wong; C K Wong; W H Leung
Journal:  Postgrad Med J       Date:  1990-05       Impact factor: 2.401

Review 2.  Immunological adverse effects of anticonvulsants. What is their clinical relevance?

Authors:  F De Ponti; S Lecchini; M Cosentino; C M Castelletti; A Malesci; G M Frigo
Journal:  Drug Saf       Date:  1993-03       Impact factor: 5.606

Review 3.  Voltage-gated sodium channel as a target for metastatic risk reduction with re-purposed drugs.

Authors:  Tomas Koltai
Journal:  F1000Res       Date:  2015-07-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.